Patient-Derived Xenograft (PDX) Model Market to Reach US$ 1.12 Billion by 2031, Fueled by Expanding Precision Oncology and Biomarker Discovery Applications

United States of America - November 14, 2025 - According to The Insight Partners, the global Patient-Derived Xenograft (PDX) Model Market is on an accelerated growth trajectory and is projected to reach US$ 1,119.36 million by 2031, rising from US$ 468.75 million in 2024. According to the latest industry analysis, the market is expected to register a robust CAGR of 13.5% during the forecast period of 2025-2031. This growth is attributed to increasing adoption of PDX technologies in oncology drug development, translational research, biomarker discovery, and personalized medicine programs.

PDX models-derived directly from patient tumor tissues and engrafted into immunodeficient mice or rats-provide a clinically relevant alternative to conventional cell-line-based models. These systems offer unparalleled accuracy in predicting human therapeutic response, supporting pharmaceutical companies in reducing drug development timelines and improving clinical trial success rates.

Check valuable insights in the Patient-Derived Xenograft Model Market report. You can easily get a sample PDF of the report https://www.theinsightpartners.com/sample/TIPRE00021693/?utm_source=OpenPR&utm_medium=10826

PDX Models Take Center Stage in Modern Oncology Research
With global cancer prevalence rising, the demand for more predictive and physiologically relevant preclinical models has become urgent. PDX models have emerged as a critical solution by preserving the heterogeneity, histological architecture, and genomic characteristics of human tumors.
Pharmaceutical firms and contract research organizations (CROs) are increasingly adopting PDX models to evaluate drug efficacy, study mechanisms of resistance, test combination therapies, and validate novel therapeutic targets.

Key Growth Drivers of the PDX Model Market

1. Rising R&D Investments in Oncology
As oncology continues to dominate global drug development pipelines, companies are expanding their use of PDX repositories to accelerate preclinical evaluation and candidate screening.
2. Expansion of Precision Medicine Initiatives
PDX models are being integrated into clinical decision-making workflows-helping identify patient-specific therapy responses and optimize treatment regimens.
3. Increasing Use in Biomarker and Genomic Research
The combination of PDX models with next-generation sequencing (NGS), CRISPR/Cas9 technologies, and multi-omics profiling is enabling deeper insights into tumor biology.
4. Strong Adoption by CROs and Academic Research Institutions
CROs are scaling their catalogs to include humanized PDX models, metastatic PDX models, and PDX-derived organoids (PDxOs), broadening service offerings to pharma and biotech partners.

Market Segmentation

By Type
• Mice Model
• Rats Model

By Tumor Type
• Gastrointestinal Tumor Model
• Gynecological Tumor Model
• Respiratory Tumor Model
• Other Tumor Model

By Application
• Preclinical Drug Development
• Biomarker Analysis
• Translational Research
• Biobanking

By End User
• Pharmaceutical and Biotechnology Companies
• Academic and Research Institutes
• Contract Research Organizations (CROs)

Competitive Landscape

The market is moderately fragmented with leading players expanding their PDX repositories, strengthening partnerships, and investing in advanced characterization platforms. Key companies include:
• Noble Life Sciences
• Charles River Laboratories International Inc
• Crown Bioscience Inc
• Experimental Pharmacology & Oncology Berlin-Buch GmbH
• Hera BioLabs
• Oncodesign Services
• WuXi AppTec Co. Ltd.
• BioDuro LLC
• XenTech SAS
• Shanghai LIDE Biotech Co. Ltd.
Strategies such as biobank expansion, acquisition of rare tumor models, and development of humanized immune system (HIS)-PDX platforms are shaping the competitive dynamics.

For detailed insights, regional breakdowns, and strategic forecasts, access the full Patient-Derived Xenograft Model Market report at: https://www.theinsightpartners.com/buy/TIPRE00021693?utm_source=OpenPR&utm_medium=10826

Future Outlook

The PDX Model Market is expected to undergo significant transformation between now and 2031, with advancements including:
• Increased integration of AI and machine learning for predicting tumor behavior
• Rapid expansion of HIS-PDX models that more accurately simulate patient immune responses
• Growth of PDX-derived organoids supporting high-throughput screening
• Enhanced collaboration between global pharma companies and PDX service providers
• Broader adoption in rare cancer research and pediatric oncology

About the Study

This market assessment provides an in-depth analysis of current trends, competitive landscape, market drivers, and opportunities shaping the global PDX model sector. It evaluates product pipelines, regulatory influences, end-user adoption patterns, funding trends, and technological advancements expected to drive market growth through 2031.

Related Reports

• PDX models Market - https://www.theinsightpartners.com/reports/pdx-models-market
• Humanized Mice Model Market - https://www.theinsightpartners.com/reports/humanized-mice-model-market
• Mice Model Market - https://www.theinsightpartners.com/reports/mice-model-market
• Patient Derived Xenograft Models Professional Market - https://www.theinsightpartners.com/reports/patient-derived-xenograft-models-professional-market

Contact Us:

If you have any queries about this report or if you would like further information, please get in touch with us:
Contact Person: Ankit Mathur
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
Also Available in: 日本 | 한국어 | Français | لعربية< | 中文 | Italiano | Español | Deutsch

About The Insight Partners

The Insight Partners is among the leading market research and consulting firms in the world. We take pride in delivering exclusive reports along with sophisticated strategic and tactical insights into the industry. Reports are generated through a combination of primary and secondary research, solely aimed at giving our clientele a knowledge-based insight into the market and domain. This is done to assist clients in making wiser business decisions. A holistic perspective in every study undertaken forms an integral part of our research methodology and makes the report unique and reliable.

This release was published on openPR.